Study on P21-Activated Kinases and Cancer Survival
Author Information
Author(s): Vo Jessie M., La Linh M., Anderson Ananda V., Alanazi Abdulaziz H., Somanath Payaningal R.
Primary Institution: Clinical and Experimental Therapeutics, University of Georgia
Hypothesis
Genetic alterations in P21-activated kinases could be linked to reduced overall patient survival.
Conclusion
The study found that elevated PAK expression is associated with poorer survival outcomes in prostate and breast cancer patients.
Supporting Evidence
- Elevated PAK expression was linked to poorer survival in prostate and breast cancer.
- PAK2 alterations were associated with significant differences in survival outcomes in pancreatic cancer.
- PAK1 expression was significantly associated with reduced survival in skin cancer.
Takeaway
This study looked at how changes in certain proteins called PAKs might affect how long cancer patients live. It found that some PAKs can help doctors understand which patients might not do as well.
Methodology
Data from the cBioPortal for Cancer Genomics was analyzed, focusing on genetic alterations in PAK isoforms and their correlation with patient survival across various cancer types.
Potential Biases
Potential off-target effects or incomplete knockdown in RNAi data may affect results.
Limitations
The study relies on public genomic databases, which may introduce biases due to varying data quality and underrepresentation of certain cancer types.
Participant Demographics
The study analyzed data from 31,661 tumor samples across various cancer types.
Statistical Information
P-Value
0.0004
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website